The Artificial Pancreas is Finally Coming to Market

  • May 2017

According to a story in Tuesday’s USA Today, the first artificial pancreas systems are beginning to come to market.

The artificial pancreas is a nickname given to wearable devices that take on the dual task of monitoring glucose levels as well as administering insulin. Also referred to as a “closed-loop” system because  the devices do their work with no help from humans.

The first system to hit the market is the MiniMed 670G from Medtronic. Other companies have active studies underway and hope to bring their products to the marketplace later this year or in 2018. Those companies include startup Bigfoot Biomedical, Insulet, and a partnership between Dexcom, Tandem, and TypeZero.

The article states that these systems actually aren’t an option for most diabetes, many of whom have type 2 diabetes. The artificial pancreas is for the 10% of diabetes patients who have type 1 diabetes.

Read the entire article at USA Today.

You may also like

  • Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes

    GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed…

  • Liraglutide Increases Insulin Sensitivity Independent of Weight Loss, Study Shows

    Liraglutide, the glucagon-like peptide-1 receptor (GLP-1R) agonist used to treat type 2 diabetes and obesity, can lead to rapid improvement in insulin sensitivity, according to a study recently published in Diabetes. “We know that GLP-1R agonists promote weight loss, but we were surprised to find that the GLP-1R agonist liraglutide also has rapid effects on…

Find more in